Eon Rolls Out Doxycycline Monohydrate.
NEW YORK -- Eon Labs Manufacturing Inc. has debuted doxycycline monohydrate capsules in 50-and 100-mg. strengths. The product is bioequivalent to Oclassen Pharmaceuticals' Monodox brand.
Prescriptions for the broad-spectrum antibiotic have increased 27% in the last 12 months, with Monodox generating over $50 million in that period, according to Frank Della Fera, vice president of sales and marketing for Eon, one of the country's leading generic pharmaceutical firms.
"The introduction of doxycycline monohydrate, our second exclusive generic thus far this year, is part of our strategy to be the first to market with niche, as well as blockbuster generics," notes Della Fera. "Doxycycline is one of many new approvals for Eon as we continue to be one of the most prolific marketers of new abbreviated new drug applications [ANDAs] in the generics industry."
Several other generic drug manufacturers have either recently received Food and Drug Administration approvals of their ANDAs (or clearance from Canadian authorities) or have begun marketing drugs previously cleared by the regulatory agency.
Those firms include:
* Taro Pharmaceuticals Inc. The Canadian company, a unit of Taro Pharmaceutical Industries Ltd., received notice from Health Canada's therapeutic products program (TPP) that its ANDA submission for nine strengths of warfarin sodium tablets USP had been approved. The product is an anticoagulant indicated for the prevention and treatment of blood-clotting disorders. Taro's products are the first generic warfarin sodium tablets to be cleared by the TPP.
* Teva Pharmaceuticals USA. The company has introduced enalapril maleate tablets USP in 2.5, 5,10 and 20mg. The product is AB rated and bioequivalent to Merck & Co.'s Vasotec, a hypertension treatment. The company has also received tentative approval for loratadine 10-mg. tablets, a generic version of Schering-Plough Corp.'s Claritin allergy medication.
* F.H. Faulding & Co. The company, through its Faulding Pharmaceuticals unit, has launched enalaprilat injection and enalapril maleate tablets. The company is also marketing (under its Purepac name) the first generic version of etodolac extended-release 400-mg. tablets, the generic equivalent of Wyeth-Ayerst Laboratories' Lodine XL tablet. Faulding has 14 products awaiting FDA approval.
* Alpharma USPD. The company has debuted sucralfate suspension (1 g./10 ml.) in unit-dose packaging. The product is equivalent to Aventis Pharmaceuticals' Carafate suspension. Alpharma is marketing the product, indicated for the short-term treatment of active duodenal ulcer, under the Xactdose label.
* URL Mutual. A new unit-of-use program for over 30 products has been announced by the generic drug manufacturer. "Pharmacies nationwide will realize immediate benefit using our unit-of-use program," notes Greg Hayer, vice president of sales. "Dispensing in unit-of-use allows pharmacists to quickly and accurately fill prescriptions while increasing inventory turns, improving cash flow and maximizing return on their inventory investment -- saving both time and money."
|Printer friendly Cite/link Email Feedback|
|Publication:||Chain Drug Review|
|Article Type:||Brief Article|
|Date:||Sep 25, 2000|
|Previous Article:||Study Reflects Role of Generics in Canada.|
|Next Article:||NAPM Workshop to Deal With Scientific, Regulatory Concerns.|